Italiano | English
AGIMM (acronym of AIRC-Gruppo Italiano Malattie Mieloproliferative) represents a group of italian scientists who, thanks to AIRC 5 per 1000 fundings , joined together in a research programme focused on "classic" chronic myeloproliferative neoplasms. These disorders, which are characterized by the involvement of a multipotent stem cell of the bone marrow, include: Polycythemia Vera, Essential Thrombocytemia, Primary Myelofibrosis and Secondary Myelofibrosis following Polycythemia Vera or Essential Thrombocytemia. During the last years significant progresses have been made in basic and applied research in these disorders which, in 2005, led to the identification of the first recurrent molecular abnormality, the JAK2 V617F point mutation.
This project has the purpose to define further the molecular mechanisms responsible for these disorders, with the aim of translating the informations from the laboratory to the patient in a short time, refining the prognosis's definition and testing new therapies for the control of disease and the improvement of quality of life. The experimental hypothesis is that by employing advanced techniques in a multi-faced approach we could have the chance to identify new tumor markers and new, more selective, therapeutic targets.
AGIMM is composed of seven groups, coordinated by prof. Alessandro Maria Vannucchi, for a total of 68 researchers; greater than one third are medical doctors working in the laboratory and making clinical research at the same time. This double role represents a fundamental aspect of the program that should allow the prompt clinical validation of the experimental data and vice versa.